Resources Archive - Page 3 of 49

KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...

Fully Automated HTS Platform for Screening Diverse Targets

High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates....

Unleashing the Power of Spectral Shift Technology

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...

HTS Platform to Advance Molecular Glue Discovery

Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Screening Strategies for Molecular Glue Discovery

Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...

Webinar: Target Deconvolution and Tractability Assessment

Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug discovery and target identification. By using...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...